Product

New Data Show Statistically Greater Improvements in Clinical Outcomes with Subcutaneous Infliximab, Compared to Intravenous Infliximab, in Patients With Rheumatoid Arthritis

Retrieved on: 
Tuesday, May 31, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Joint, Royal commission, Product, Toulouse III - Paul Sabatier University, Disease, NRI, Immune system, The American Journal of Managed Care, Randomized controlled trial, Pain, Swelling, European Commission, Degenerative disease, EULAR, CGMP, EC, Celltrion, III, Observation, Poster, Biosimilar, US Foods, Medication package insert, IV, Adult, Rheumatoid arthritis, FDA, IBD, Infliximab, Inflammatory bowel disease, Rheumatology, Congress, American Journal, Senior, Disease-modifying antirheumatic drug, Risk, Population, European Medicines Agency, Patient, Human, RA, Marketing, Diagnosis, Medical device, Pharmaceutical industry, EU

The post-hoc study investigated whether the numerical advantage of SC infliximab compared to IV, shown in most efficacy parameters at weeks 30 and 54, was statistically significant.

Key Points: 
  • The post-hoc study investigated whether the numerical advantage of SC infliximab compared to IV, shown in most efficacy parameters at weeks 30 and 54, was statistically significant.
  • Results showed a statistically significant difference in favour of SC compared to IV-treated patients at week 30 in almost all clinical variables, including low disease activity rates and remission rate.
  • Efficacy of Subcutaneous Infliximab (CT-P13 SC) Compared with Intravenous Infliximab in Rheumatoid Arthritis: A Post-hoc Analysis of a Phase 3 Randomized Controlled Trial.
  • A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 30-week results from part two of a Phase I/III randomised controlled trial in patients with rheumatoid arthritis.

Global Industrial Gases Market Report (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 31, 2022
Oil, Gas, Energy, Hydrogen, Helium, R, Coronavirus, Magnetic resonance imaging, Patient, MRI, Air Products & Chemicals, Health, Gas, Transport, COVID-19, Research, Method, Product, Hospital, Safety, Oxygen, Growth, Animal, Natural gas

Industrial gases refer to the gases produced in large quantities for usage in industrial processes.

Key Points: 
  • Industrial gases refer to the gases produced in large quantities for usage in industrial processes.
  • In recent years, technological innovations in the usage of various industrial gases have bolstered the growth of the market.
  • Moreover, several international non-profit organizations, such as the European Industrial Gases Association, provide manufacturers with expert advice on the production, transport, storage and utilization of industrial gases.
  • What are the major regions in the global industrial gases market?

The Worldwide Synthetic Biology Industry is Expected to Reach $37.8 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 31, 2022
Health, Technology, Other Technology, Genetics, Other Health, Research, Science, Department, Department of Biotechnology, DST, CSIR, Department of Science and Technology (India), Enzyme, Food, Genetic engineering, Agriculture, Science, Investment, SOSV, Synthetic biology, Industrial Research Limited, DBT, COVID-19, Oligonucleotide, Institute, Council, Council for Scientific and Industrial Research, Product, Nanotechnology, Therapy, CAGR, Growth, Application, Drug discovery, Genetically modified organism, Pharmaceutical industry, Fine chemical, EU, Technology, Biotechnology

The global synthetic biology market is expected to grow from US$ 10,544.16 million in 2021 to US$ 37,850.85 million by 2028; it is estimated to grow at a CAGR of 20.0% from 2021 to 2028.

Key Points: 
  • The global synthetic biology market is expected to grow from US$ 10,544.16 million in 2021 to US$ 37,850.85 million by 2028; it is estimated to grow at a CAGR of 20.0% from 2021 to 2028.
  • The report highlights trends prevailing in the synthetic biology market and factors driving its growth.
  • The increasing investments in synthetic biology and the rising number of start-ups are driving the market growth.
  • Synthetic biology is the science of designing, altering, and building simple organisms to perform specific therapeutic or industrial utilities.

American Society of Agricultural and Biological Engineers (ASABE) launches its eLibrary on Impelsys' iPC Scholar 3.0

Retrieved on: 
Tuesday, May 31, 2022
Engineering, Annual general meeting, IPC, Food, Multimedia, The Society, Level 3, Solution, Science and technology in Asia, Society for Scholarly Publishing, ASABE, Research, SSP, Capability Maturity Model Integration, Society, Product, Technology, Publishing, Publication, Mobile phone, Public relations, Impelsys

The first phase of the migration process has gone live with journals and will soon be followed by ASABE's other publications.

Key Points: 
  • The first phase of the migration process has gone live with journals and will soon be followed by ASABE's other publications.
  • The new eLibrary on iPC Scholar 3.0 platform accentuates an enhanced user experience for ASABE's individual and organizational members.
  • With this launch, we are looking forward to migrating all our content and digital assets to the iPC Scholar 3.0 platform."
  • ASABE is an international scientific and educational organization dedicated to the advancement of engineering applicable to agricultural, food, and biological systems.

American Society of Agricultural and Biological Engineers (ASABE) launches its eLibrary on Impelsys' iPC Scholar 3.0

Retrieved on: 
Tuesday, May 31, 2022
Engineering, Annual general meeting, IPC, Food, The Society, Level 3, Solution, Science and technology in Asia, Society for Scholarly Publishing, ASABE, Research, SSP, Capability Maturity Model Integration, Society, Product, Technology, Publishing, Publication, Mobile phone, Public relations, Impelsys

The first phase of the migration process has gone live with journals and will soon be followed by ASABE's other publications.

Key Points: 
  • The first phase of the migration process has gone live with journals and will soon be followed by ASABE's other publications.
  • The new eLibrary on iPC Scholar 3.0 platform accentuates an enhanced user experience for ASABE's individual and organizational members.
  • With this launch, we are looking forward to migrating all our content and digital assets to the iPC Scholar 3.0 platform."
  • ASABE is an international scientific and educational organization dedicated to the advancement of engineering applicable to agricultural, food, and biological systems.

Akur8 Partners with Duck Creek Technologies to Offer Fully Integrated, Best-in-Class Pricing Software Solutions to P&C Carriers

Retrieved on: 
Tuesday, May 31, 2022
Technology, Mobile, Wireless, Insurance, Finance, Other Technology, Professional Services, Software, Data Management, Other Professional Services, Product, Risk, Policy, Nasdaq, Generali, Insurance, Uncertainty, Automation, P&C, Algorithm, Industry, Partnership, Technology, Safety, AXA, Machine learning, Software as a service, Founder, CEO, Risk management, Sapiens

Akur8 is a proud partner of Duck Creek Technologies, one of the largest P&C insurance technology marketplaces worldwide, and we are excited for our integration to be available for mutual customers on the Duck Creek Content Exchange .

Key Points: 
  • Akur8 is a proud partner of Duck Creek Technologies, one of the largest P&C insurance technology marketplaces worldwide, and we are excited for our integration to be available for mutual customers on the Duck Creek Content Exchange .
  • Jointly, Akur8s integrated pricing solution within Duck Creek Policy and Duck Creek Rating provide an end-to-end solution that enables insurers to accelerate time-to-market by building and deploying rates faster, said Andy Yohn, Vice President of Product Development at Duck Creek Technologies.
  • Duck Creek Technologies (Nasdaq: DCT) is a leading provider of core system solutions to the P&C and general insurance industry.
  • Duck Creeks functionally-rich solutions are available on a standalone basis or as a full suite , and all are available via Duck Creek OnDemand.

World Clinical Trial Supplies Market Size, Share & Trends Analysis & Forecast Report 2022-2030: Increasing Volume of Clinical Trials Coupled with Growing Complexities of Conducting These Trials - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 31, 2022
Health, Clinical Trials, Product, Product-service system, Biopharmaceutical, Clinical trial, USD, COVID-19, Research, FDA, Genetics, United Press International, Chapter Three, Biotechnology, EMA, III, DTP, Hospital, Technology, Movement, CAGR, Growth, Medical device, Pharmaceutical industry, Vaccine

The global clinical trial supplies market size is expected to reach USD 3.40 billion by 2030, registering a CAGR of 6.4%

Key Points: 
  • The global clinical trial supplies market size is expected to reach USD 3.40 billion by 2030, registering a CAGR of 6.4%
    This growth can be attributed to the increasing volume of clinical trial studies coupled with the growing complexity of conducting these trials.
  • To enhance their foothold in the market, key companies are adopting various plans and policies to gain a higher market share.
  • The clinical trial and pharmaceutical industry is anticipated to witness steady growth, which, in turn, will increase the demand for clinical trial supplies, thereby driving the market growth.
  • Clinical Trial Supplies Market Variables, Trends, & Scope
    3.1.6 Clinical Trial Supplies Market: Impact of COVID-19

Galderma to Present Extensive New Clinical Data Across Its Portfolio of Neuromodulators, Fillers and Biostimulators at the IMCAS World Congress 2022

Retrieved on: 
Tuesday, May 31, 2022
Research, Infectious Diseases, Clinical Trials, Health, Cosmetics, Pharmaceutical, General Health, Retail, Science, Physician, Product, Family, Dermatology, Patient, Florence Picaut, Toxin (comics), Botulinum toxin, FDA, Water, Partnership, Life, Eyebrow, Safety, Bont, PLLA, Skin, Lidocaine, Achievement, Pharmaceutical industry, Paint, Vaccine, Wood drying, Galderma, Sculptra, EU, Ipsen

The latest long-term effectiveness and safety of Sculptra, the original and only poly-L-lactic acid (PLLA) approved by the FDA, will also be presented at IMCAS 2022.

Key Points: 
  • The latest long-term effectiveness and safety of Sculptra, the original and only poly-L-lactic acid (PLLA) approved by the FDA, will also be presented at IMCAS 2022.
  • Because we understand that the skin were in shapes our lives, we are advancing dermatology for every skin story.
  • For more information: www.galderma.com
    Alluzience (liquid botulinum toxin type A) is the first ready-to-use BoNT-A liquid neuromodulator formulation to be introduced in Europe.
  • Dysport has more than 30 years of clinical experience Globally for therapeutic indications and 13 years for aesthetics indications, with extensive clinical evidence of safety and efficacy.

Milan Dordevic accepted into Forbes Technology Council

Retrieved on: 
Friday, May 27, 2022
Product, Operational technology, Education, Criterion, Forbes, Verification, CIOS, New product development, K-12, Council, Industry, Partnership, Identity, YEC, Technology, Q&A, Lock Down, Exam proctoring, Consultant, Public relations

SCOTTSDALE, Ariz., May 27, 2022 /PRNewswire-PRWeb/ -- Milan Dordevic, Director of Product Development at Proctorio, a leading online proctoring company, has been accepted into Forbes Technology Council, an invitation-only community for world-class CIOs, CTOs, and technology executives.

Key Points: 
  • Milan Dordevic, Director of Product Development at Proctorio, a leading online proctoring company, has been accepted into Forbes Technology Council, an invitation-only community for world-class CIOs, CTOs, and technology executives.
  • SCOTTSDALE, Ariz., May 27, 2022 /PRNewswire-PRWeb/ -- Milan Dordevic, Director of Product Development at Proctorio, a leading online proctoring company, has been accepted into Forbes Technology Council, an invitation-only community for world-class CIOs, CTOs, and technology executives.
  • Milan Dordevic was vetted and selected by a review committee based on the depth and diversity of his experience.
  • "We are honored to welcome Milan Dordevic into the community," said Scott Gerber, founder of Forbes Councils, the collective that includes Forbes Technology Council.

Webscale Appoints Sophie Maler as VP Product

Retrieved on: 
Friday, May 27, 2022
Cloud, Azure, Olympus, Software, Oracle, DevOps, CA Technologies, Leadership, Automation, Regal Cinemas, Fortune 1000, B2E, Marketing, Commerce, Elron, Login, Product marketing, CO, Google Cloud Platform, Compliance, Technology, Microsoft Azure, Amazon Web Services, Machine learning, LinkedIn, Microsoft, Twitter, Swarovski, Noise, Acquisition, Amazon, CA, GLOBE, Online shopping, Product, Vesta, Unilever, Facebook, Scalability

SANTA CLARA, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Webscale , the fastest, most secure cloud platform for modern commerce, has announced the appointment of Sophie Maler as its new VP of Product, responsible for product direction and technology roadmap execution.

Key Points: 
  • SANTA CLARA, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Webscale , the fastest, most secure cloud platform for modern commerce, has announced the appointment of Sophie Maler as its new VP of Product, responsible for product direction and technology roadmap execution.
  • Sophie is an industry veteran with over 25 years of experience in software engineering, product management and marketing across startups and large multinational corporations.
  • She joins Webscale from Vesta, a leading transaction guarantee platform for online purchases, where she led Product Marketing.
  • Highlights of her leadership roles include Group Product Manager at Oracle, Head of Marketing at Login with Amazon, and Head of Product Marketing at AWS Identity.